Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial biotechnology company, announced that its management team will participate in two upcoming investor conferences in May 2026. The company is scheduled to present at the RBC Capital Markets Global Healthcare Conference on May 19 in New York and at A.G.P.'s Annual Virtual Healthcare Conference on May 20. This announcement comes as Tonix continues to advance its pipeline of treatments for central nervous system (CNS) and immunology conditions in areas of high unmet medical need.
Tonix's flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), was recently approved as the first new treatment for fibromyalgia in more than 15 years. The company's CNS commercial infrastructure supports its marketed products, including acute migraine treatments Zembrace SymTouch and Tosymra. Beyond fibromyalgia, Tonix is exploring the potential of TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder. Additionally, the CNS pipeline includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, a rare disease.
In immunology, Tonix is developing monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These programs underscore the company's commitment to addressing serious conditions with limited treatment options. The participation in the RBC Capital Markets Global Healthcare Conference and A.G.P.'s Annual Virtual Healthcare Conference provides an opportunity for Tonix to present its progress and strategic vision to the investment community.
For investors and industry observers, these conferences offer a platform to gain insights into Tonix's commercial momentum and pipeline advancements. The company's focus on CNS and immunology therapies positions it in high-growth areas with significant patient needs. The recent approval of TONMYA marks a milestone for fibromyalgia patients, who have had limited therapeutic options for over a decade. The ongoing clinical trials for additional indications could further expand the drug's market potential.
The full press release is available at https://ibn.fm/ZZpG2. For the latest news and updates on Tonix Pharmaceuticals, visit the company's newsroom at https://ibn.fm/TNXP.
Tonix Pharmaceuticals is a fully integrated commercial-stage biotechnology company dedicated to developing treatments for CNS and immunology conditions. The company's product development candidates are investigational new drugs or biologics, and their efficacy and safety have not been established for any indication. The investor conferences in May provide a forum for Tonix to communicate its strategy and progress to shareholders and potential investors.
